Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 11 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

895 Engineering GPRC5D multispecific antibodies: parallel engineering to optimize affinity, developability, and IP

  • Benjamin Doranz1
  • Joseph Rucker1
  • Ileine Sanchez1
  • Kyle Doolan1
  • Breanna Tyrell1
  • Hayley Roth1
  • Ross Chambers1
  • Trevor Barnes1
  • Alexander Hobby1
  • Daniel Rogers1
  • Valerie Fiers1
  • Amelia Snyde1
  1. 1Integral Molecular, Philadelphia, PA, USA
Open at sourcePDFDOICite

Related

  1. Bridging the gap: towards a digital twin to optimize therapeutic cell-seeding strategies in nerve tissue engineering
    Owein Guillemot-Legris, Maxime Berg, Poppy O. Smith +2
    Journal of the Royal Society InterfacePeer-reviewedCC BY 4.0Full textNeuroscienceHAL
  2. An interpretable open platform for sequence-based antibody developability prediction
    H. N. Nguyen, D. Kothiwal, Y. Su +4
    bioRxivPreprintCC BYFull textBioinformatics & computational biologybioRxiv
  3. kitAb: an automated framework for assay-specific antibody developability modeling and large-scale landscape analysis
    E. Trofimova, E. Shaburova, D. Antonets +1
    bioRxivPreprintCC BYFull textBioinformatics & computational biologybioRxiv
  4. Pair-complete structural gating enables Pareto optimization of de novo cyclic peptides with preserved binding geometry and improved developability
    Y. Hou, Y. Zhang, Z. Liu +7
    bioRxivPreprintCC BY-NC-NDFull textBioinformatics & computational biologybioRxiv
  5. FLAb2: Benchmarking reveals that protein AI models cannot yet consistently predict developability properties
    Michael Chungyoun, J. Robert Gray
    PatternsPeer-reviewedCC BY17 citedImmunologyMedical imaging & radiologyOpenAlex

Cite

BibTeXRIS
BibTeX
@article{doranz2026engineering,
  title = {{895 Engineering GPRC5D multispecific antibodies: parallel engineering to optimize affinity, developability, and IP}},
  author = {Benjamin Doranz and Joseph Rucker and Ileine Sanchez and Kyle Doolan and Breanna Tyrell and Hayley Roth and Ross Chambers and Trevor Barnes and Alexander Hobby and Daniel Rogers and Valerie Fiers and Amelia Snyde},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0895},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0895},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 895 Engineering GPRC5D multispecific antibodies: parallel engineering to optimize affinity, developability, and IP
AU  - Benjamin Doranz
AU  - Joseph Rucker
AU  - Ileine Sanchez
AU  - Kyle Doolan
AU  - Breanna Tyrell
AU  - Hayley Roth
AU  - Ross Chambers
AU  - Trevor Barnes
AU  - Alexander Hobby
AU  - Daniel Rogers
AU  - Valerie Fiers
AU  - Amelia Snyde
PY  - 2026
DA  - 2026/11/06
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0895
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0895
SN  - 2051-1426
ER  -